Laser Neurolysis
Customize your policy alerts
Sign up for Aetna Policy 0552 alerts
Get alerted when Policy 0552 changes without checking for updates manually.
Monitor payer policy activity
This policy governs Aetna's coverage stance on laser neurolysis (noninvasive laser application to peripheral nerves) for treatment of pain-related indications and lists indications considered experimental/investigational. It applies to Aetna plan providers and members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Experimental and Investigational — Not covered
Not covered (considered experimental and investigational) for the following indications due to insufficient evidence of effectiveness:
List is not all-inclusive per policy.
The ICD-10 codes listed in this policy are not covered when billed for the indications specified in this Clinical Policy Bulletin. This list is not all-inclusive; claims using the ICD-10 codes below for the investigational indications described in the policy are subject to denial or prior authorization failure.
Coding
| 64600-64610 | Destruction by neurolytic agent, trigeminal nerve |
| 64620-64640 | Destruction by neurolytic agent, intercostal nerve, paravertebral facet joint nerve, or pudendal nerve |
| 64702-64704 | Neuroplasty, digital, one or both, same digit or nerve of hand or foot |
| 64708-64714 | Neuroplasty, major peripheral nerve, arm or leg, open |
| 64727 | Internal neurolysis, requiring the use of operating microscope (List separately in addition to code for neuroplasty) |
| G54.6 | Phantom limb syndrome with pain |
| G56.00-G56.03 | Carpal tunnel syndrome |
| G56.40-G56.42 | Causalgia of upper limb (CRPS II of upper limb) |
| G57.70-G57.73 | Causalgia of lower limb (CRPS II of lower limb) |
| G90.50-G90.59 | Complex regional pain syndrome I (CRPS I) |
Provider Actions and Billing Notes
Prior authorization expectation — unlikely to approve
Aetna considers laser peripheral nerve block (laser neurolysis) experimental and investigational for specified indications and therefore it would not meet medical necessity; prior authorization approvals are unlikely for these indications.
Conservative therapy preference for CRPS
For complex regional pain syndrome (CRPS), the literature emphasizes physiotherapy-based interventions (e.g., graded motor imagery, mirror therapy) over laser neurolysis; conservative modalities are preferred given the low or very low quality evidence for most interventions and only small, short-term effects reported for laser therapy.
Supporting clinical documentation required
Include diagnosis and supporting diagnostic testing/results when claiming benefit from laser neurolysis; studies of carpal tunnel specified objective nerve conduction parameters for participant selection.
- Document clinical diagnosis (e.g., carpal tunnel syndrome) and relevant diagnostic testing.
- Include nerve conduction study results such as CMAP distal latency and sensory nerve action potential values reported in the carpal tunnel study.
Denial risk for experimental/investigational indications
Claims for laser peripheral nerve block (laser neurolysis) for indications listed as experimental and investigational (for example, carpal tunnel syndrome, CRPS, facet joint pain, phantom limb pain, sacroiliac joint pain) are subject to denial due to insufficient evidence of effectiveness.
Background
Laser neurolysis is the non‑invasive application of laser to peripheral nerves and is considered a form of low‑level laser therapy. It has been investigated primarily in small, uncontrolled studies for conditions such as carpal tunnel syndrome and facet joint pain, but available evidence is limited by small sample sizes, short follow‑up, and lack of control groups.
Definitions
Conservative Treatment Requirements
Imaging and Diagnostic Requirements
Carpal tunnel study nerve conduction parameters
In the carpal tunnel study, investigators selected participants using objective nerve conduction parameters such as compound muscle action potential distal latency >4.0 ms and sensory nerve action potential >3.7 ms; include these reported measures when documenting cases similar to the study population.
- CMAP distal latency greater than 4.0 milliseconds.
- Sensory nerve action potential greater than 3.7 milliseconds.
Not Covered / Exclusions
The following indications are not covered (considered experimental and investigational) due to insufficient evidence of effectiveness: carpal tunnel syndrome; complex regional pain syndrome (CRPS I and II); facet joint pain; phantom limb pain; and sacroiliac joint pain. Corresponding ICD‑10 codes listed in the policy (for example, G56.00–G56.03 for carpal tunnel syndrome; G90.50–G90.59 and G56.40–G56.42 for CRPS; G54.6 for phantom limb pain; M53.3 for sacroiliac joint pain) are not covered when used for these indications.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.